The 8 most recent market catalysts affecting $ELVN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiated coverage on Enliven Therapeutics (ELVN) with an Outperform rating, signaling strong confidence in the company's lead drug candidate, ELVN-001. This is a sig…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 55
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating
William Blair's initiation of coverage on Enliven Therapeutics with an Outperform rating signals a positive outlook from a reputable financial institution. This event is significan…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78
Barclays analyst Etzer Darout has initiated coverage on Enliven Therapeutics (ELVN) with an 'Overweight' rating and a $78 price target. This is a positive development for ELVN as i…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73
Mizuho analyst Salim Syed has maintained an 'Outperform' rating on Enliven Therapeutics and raised the price target from $62 to $73. This action signals increased confidence from a…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82
Stifel analyst Dara Azar has maintained a 'Buy' rating on Enliven Therapeutics (ELVN) and raised the price target from $80 to $82. This action signals continued analyst confidence …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Goldman Sachs analyst Salveen Richter has maintained a 'Buy' rating on Enliven Therapeutics (ELVN) and raised the price target from $67 to $80. This action signals a stronger convi…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate
Enliven Therapeutics (ELVN) announced its Q2 earnings per share, reporting a loss of $(0.49), which was 22.5% worse than the analyst consensus estimate of $(0.40). This significant…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67
Goldman Sachs analyst Salveen Richter maintained a 'Buy' rating on Enliven Therapeutics (ELVN) and raised the price target from $59 to $67. This action signals increased analyst co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.